IRIS

Phosphine

CASRN 7803-51-2

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (146 pp, 20 K) last updated: 01/31/1987

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
None 3 x 10-4 Body weight and clinical parameters NOEL : 2.6 x 10-2
mg/kg-day
100 Medium

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (146 pp, 20 K) last updated: 07/01/1995

System RfC (mg/m3) Basis PoD Composite UF Confidence
Other 3 x 10-4 Decreased body weight NOAEL (HEC): 2.5 x 10-1
mg/m3
1000 Low

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (146 pp, 20 K) last updated: 09/01/1992

WOE Characterization Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Based on inadequate data in animals and no tumor data in humans. While phospine has not been associated with cancer in humans, there is some evidence of chromosomal damage (transient chromatid deletions, gaps and breaks, persistent chromosomal translocations). A relationship between these genetic effects and the development of cancer in humans is sometimes postulated.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (146 pp, 20 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (146 pp, 20 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.